Adverse sounds serious, but really:

About 105 vaccine recipients reported at least one AEFI symptoms following COVID-19 vaccination (incidence proportion 6.4%, 95% CI: 5.3%, 7.7%). All AEFI reported were minor which were managed by tablet paracetamol and subsided after 1–2 days. Fever (65, 3.98%) was the most commonly reported AEFI followed by myalgia (54, 3.30%) (Fig. 1). About 48 (2.94%) study participants reported 2 or more AEFI, most common being fever with myalgia (19, 1.16%) and fever with headache (18, 1.10%). No severe or serious AEFI was reported among vaccine recipients.